N
NeuBase Therapeutics Inc
F:O7PA
NeuBase Therapeutics Inc
F:O7PA
Price:
0.159
EUR
-3.64%
Market Cap:
€5.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
N
|
NeuBase Therapeutics Inc
F:O7PA
|
US |
|
FlexShopper Inc
NASDAQ:FPAY
|
US |
|
Prosper Gold Corp
XTSX:PGX
|
CA |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of O7PA.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
O7PA
Multiples-Based Value
Not Available
N
Multiples Across Competitors
O7PA Competitors Multiples
NeuBase Therapeutics Inc Competitors
NeuBase Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
N
|
NeuBase Therapeutics Inc
F:O7PA
|
107.5m EUR | 0 | -9.2 | -9 | -8.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
368.5B USD | 6 | 87.9 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.7B USD | 5.1 | 24.4 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.5B USD | 5.9 | 20.3 | 12.7 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
112.2B USD | 9.3 | 28.3 | 21.2 | 22.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.7B USD | 5.5 | 17.6 | 13 | 14.9 | |
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR | 12.4 | 39.8 | 43.2 | 44.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.2B AUD | 2.9 | 32.4 | 10.9 | 13.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
